EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05020704

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05020704
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05020704. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-16 (actual); primary completion 2024-06-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
Acronym
EMPRESS-MI
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Placebo
Lead sponsor
NHS Greater Glasgow and Clyde (class: other)
Collaborator
University of Glasgow (class: other)

Record details

Record id
cardio:ct-nct05020704
Content hash
78f5da9323a45bb5d8952dc7596337d3b7cf4e51d7e83efa8aba99a8241d783a